Replies to post #24067 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

http://www.clpmag.com/2009/08/amdl-inc-announces-inauguration-of-new-diagnostics-subsidiary/

AMDL Inc Announces Inauguration of New Diagnostics Subsidiary
Published on August 24, 2009

AMDL Inc announces the inauguration of AMDL Diagnostics Inc (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-Sure™—AMDL’s proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.

Since the start of FY2009, AMDL has made significant progress in commercializing Onko-Sure(TM) for both the domestic and international markets, achieving planned milestones that include:

Increased market awareness both domestically and internationally;
Expanded product availability through signed distribution agreement with partners in the US, Canada, Asia and India;
Preparation for the future through a signed collaboration agreement with Mayo Clinic for development of the next-generation version of Onko-Sure test; and,
Engagement with industry experts, scientists, physicians and business development consultants in the scientific and medical communities to assist in furthering ADI’s commercializing efforts.

The establishment of a separate subsidiary allows AMDL to concentrate specific resources to the successful execution of that plan. ADI intends to achieve goals set forth in its 5-year plan by securing adequate financing, significantly broadening its distribution network, and continuing to research, develop, and commercialize current and future diagnostic products. ADI’s management believes sales of Onko-Sure test kits are likely to exceed US$100 million per year by the end of FY2014. Current projections for ADI indicate FY2009 sales of approximately $1 million and generating a small loss for the year, and sales of approximately $17 million with over $13 million in earnings in FY2010.

"Today’s announcement underscores our commitment and focus on building AMDL for the future," stated Mr. Douglas MacLellan, Chairman and CEO of AMDL Inc. "To date, our China operations have overshadowed the consequential revenue opportunity of Onko-Sure—a potentially life-saving IVD test for literally millions of cancer patients worldwide. By establishing a separate subsidiary with specific resources dedicated to the division we believe we are in a tremendously stronger position to capitalize on the cancer IVD market."

ADI will be run by Mr. Douglas MacLellan who continued, "Many exciting opportunities exist for ADI and its investors. Onko-Sure(TM) can detect and/or monitor for 14 different types of cancer, including lung, stomach, colorectal, liver, and breast cancer which according to the World Health Organization, causes the most cancer deaths every year. Our intention is to take Onko-Sure and ADI to a level our shareholders have never experienced before."

Source: AMDL


http://www.biospace.com/news_story.aspx?StoryID=208553



Radient Pharmaceuticals' Wholly-Owned Subsidiary NuVax Therapeutics Signs Exclusive License Agreement for Immune-Gene Therapeutics Technology From University of Florida Research Center

1/25/2011 8:47:39 AM

TUSTIN, CA--(Marketwire - January 25, 2011) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today, its wholly-owned subsidiary NuVax Therapeutics, Inc., ("NuVax"), has signed an exclusive license agreement with the University of Florida College of Medicine in Gainesville, Florida for the use and commercialization of four innovative and patented immune-gene therapy tools and systems developed by Dr. Lung-Ji Chang, Professor of Molecular Genetics and Microbiology at University of Florida's Research Center.

NuVax is a clinical stage pharmaceutical company developing novel immune-gene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Under the terms of today's agreement, NuVax plans to leverage the four newly licensed tools and systems for selective targeting of patient tumor cells to invoke a stronger immune response in cancer patients. The new tools and systems are anticipated to allow NuVax to develop three separate cancer therapeutics for the treatment of Multi Myeloma, Pancreatic Cancer and Lung Cancer. Financial terms of the licensing agreement are not disclosed.

Dr. Lung-Ji Chang also developed the Combined Immunogene Therapy ("CIT") -- a patented (patent issued May 25, 2004) cancer therapy owned by NuVax. CIT is a novel immune-gene therapy that works by simultaneously incorporating two genes directly into the patient's tumor cells to enhance their immune system's natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack, while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang serves as an advisor to NuVax for the continued development of CIT and other gene therapies. NuVax has full rights to CIT.

According to RPC Chairman and CEO Mr. Douglas MacLellan, "We are very excited that NuVax has negotiated and signed these exclusive licensing agreements, which further strengthen our relationship with Dr. Lung-Ji Chang and the University of Florida research team. We believe they are among the top leaders in the research and development of cancer therapies and technologies and are pleased to advance our strategic relationship with the team. We plan to leverage our experience and expertise in product development, manufacturing, regulatory approvals, and sales and marketing to fully commercialize these new therapies and technologies as rapidly as possible."

"These licensing agreements are part of NuVax's strategic initiative to expand its presence in the lucrative cancer therapy market which is estimated to be $50 billion worldwide," commented NuVax President and CEO Dr. Umesh Bhatia. "The addition of these advanced, innovative tools and systems licensed today, in addition to our current CIT technology, provides both RPC and NuVax with a highly competitive market position and we remain focused on advancing and commercializing our growing product portfolio."

[Gold Seeker]

It was a subsidiary of Radient pharmaceuticals. Claiming it still exists as a stand alone corp is just more false spin.

Originally, there was AMDL INC.

Then they acquired Jade pharmaceuticals as a subsidiary.

In 2009, AMDL created another subsidiary, AMDL Diagnostics, INC.

Later in 2009, they changed the name of AMDL, INC to Radient Pharmaceuticals, INC.

In 2010, they divested themselves of Jade Pharmaceuticals.


Just a note to add, during a conference call in 2008, it was announced that DR70 was going to be moved to a new subsidiary diagnostic division in order to spin it off for sale. AMDL wanted to be an exclusive Chinese Pharma.